Zobrazeno 1 - 10
of 26
pro vyhledávání: '"real‐world evidence study"'
Autor:
Jean‐Pierre Bronowicki, Patrick Miailhes, Bertrand Hanslik, Denis Ouzan, Dominique Larrey, Ghassan Riachi, Régine Truchi, Vincent Jouannaud, Dan Pospait, Armand Abergel, Xavier Causse, Stéphanie Perot, Jérémy Skrzypski, Astrid De Hautecloque, Axelle Spampinato, Philippe Mariot, Philippe Sogni, the Zephyr Study group
Publikováno v:
Health Science Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background and Aim The efficacy and safety profiles of elbasvir–grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The prese
Externí odkaz:
https://doaj.org/article/ee9c3ea9dabe43cda866ce4d40cbfb40
Autor:
Kamel Mohammedi, Nathalie Préaubert, Tanguy Cariou, Vincent Rigalleau, Ninon Foussard, Laurent Piazza, Céline Bairras-Martin, Thierry Couffinhal, Julien Bezin, Antoine Benard
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)
Abstract Background Screening for coronary artery disease (CAD) remains broadly performed in patients with type 2 diabetes (T2DM), although the lack of evidence. We conduct a real-world evidence (RWE) study to assess the risk of major clinical outcom
Externí odkaz:
https://doaj.org/article/25851127ab894b4eb8b21c202f508b38
Autor:
Sabrina Mueller, Fraence Gottschalk, Antje Groth, Wilhelmine Meeraus, Maurice Driessen, Thomas Kohlmann, Thomas Wilke
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-12 (2018)
Abstract Background Real-world evidence (RWE) can inform patient management decisions, but RWE studies are associated with limitations. Linkage of different RWE data types could address such limitations by enriching data and improving scientific qual
Externí odkaz:
https://doaj.org/article/d15dc5393f0043eb9d5a6f81ac159143
Autor:
Valerio Nardone, Rocco Giannicola, Diana Giannarelli, Rita Emilena Saladino, Domenico Azzarello, Caterina Romeo, Giovanna Bianco, Maria Rosaria Rizzo, Irene Di Meo, Antonio Nesci, Pierpaolo Pastina, Antonia Consuelo Falzea, Daniele Caracciolo, Alfonso Reginelli, Michele Caraglia, Amalia Luce, Luciano Mutti, Antonio Giordano, Salvatore Cappabianca, Luigi Pirtoli, Vito Barbieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Pierpaolo Correale
Publikováno v:
Life, Vol 11, Iss 11, p 1235 (2021)
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 bi
Externí odkaz:
https://doaj.org/article/62314baa55cc425bb501c2b7b1efcaef
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 4988
Background: Metformin had been recommended as the first-line treatment for type 2 diabetes since 2006 because of its low cost, high efficacy, and potential to reduce cardiovascular events, and thus death. However, dipeptidyl peptidase-4 (DPP-4) inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32916b0e21ed81b445faa6d6470a0932
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2c4772394f649fea82aefffa2ceda80
Autor:
Domenico Azzarello, Antonio Nesci, Valerio Nardone, Pierfrancesco Tassone, Diana Giannarelli, Amalia Luce, Luciano Mutti, Irene Di Meo, Alfonso Reginelli, Rocco Giannicola, Rita Emilena Saladino, Luigi Pirtoli, Daniele Caracciolo, Vito Barbieri, Maria Rosaria Rizzo, Pierosandro Tagliaferri, P. Correale, Pierpaolo Pastina, Giovanna Bianco, Caterina Romeo, Michele Caraglia, Salvatore Cappabianca, Antonio Giordano, Antonia Consuelo Falzea
Publikováno v:
Life
Volume 11
Issue 11
Life, Vol 11, Iss 1235, p 1235 (2021)
Volume 11
Issue 11
Life, Vol 11, Iss 1235, p 1235 (2021)
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b90d15be9d66293659e0c07af4932c1
http://europepmc.org/articles/PMC8621400
http://europepmc.org/articles/PMC8621400
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.